评估长期利拉鲁肽治疗对胰高血糖素分泌影响时胰高血糖素检测方法的影响
在LIBRA试验中,51例2型糖尿病患者随机接受每日皮下利拉鲁肽或安慰剂注射并随访48周,每12周行口服葡萄糖耐量试验(末次给药约24小时前)。用Mercodia法重测全部1222份样本,未重复出R&D Systems法所见慢性利拉鲁肽增强餐后胰高血糖素血症的结果,提示检测方法选择对结果解读至关重要。
要点
- Mercodia法显示利拉鲁肽组空腹胰高血糖素在12周时高于安慰剂组(P=0.01),24、36、48周无组间差异。
- Mercodia法显示各次访视两组胰高血糖素曲线下面积(AUCglucagon)均无差异。
- 两种检测法在餐后时间点相关,空腹时间点不相关,未能重复R&D Systems法结果。
核心结论
- Mercodia法未重复出R&D Systems法的胰高血糖素结果,两种检测法反应不同妨碍得出确定性结论,凸显临床研究中胰高血糖素检测方法选择的关键作用。
研究设计与样本
- LIBRA试验中51例病程2.6±1.9年的2型糖尿病患者随机接受每日皮下利拉鲁肽或安慰剂注射,随访48周,每12周行系列口服葡萄糖耐量试验(末次利拉鲁肽/安慰剂给药约24小时前)。
- 用高灵敏度和高特异性的Mercodia法重测该试验全部1222份样本的胰高血糖素。
主要发现
- Mercodia法测得空腹胰高血糖素在12周时利拉鲁肽组高于安慰剂组(P=0.01),24、36、48周无组间差异。
- Mercodia法测得各次访视两组胰高血糖素曲线下面积(AUCglucagon)均无差异。
- Mercodia法与R&D Systems法的胰高血糖素测量值在餐后时间点相关,空腹时间点不相关。
局限性
- 原文指出两种检测法的反应不同妨碍得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Glucagon-like peptide-1 agonists acutely lower serum glucagon. However, in the Liraglutide and β-Cell Repair (LIBRA) Trial, 48-week treatment with liraglutide yielded lower/unchanged fasting glucagon but, surprisingly, enhanced postchallenge glucagonemia [measured by R&D Systems (Minneapolis, MN) assay]. OBJECTIVE: Because differences between glucagon assays potentially could explain these unexpected findings, we have remeasured glucagon in all 1222 samples from this trial using the highly-sensitive/specific Mercodia assay to compare the findings between assays. DESIGN/SETTING/PARTICIPANTS/INTERVENTION: In LIBRA, 51 patients with type 2 diabetes of 2.6 ± 1.9 years duration were randomized to daily subcutaneous liraglutide or placebo injection and followed for 48 weeks, with serial oral glucose tolerance test (OGTT) every 12 weeks (with liraglutide/placebo last administered ∼24 hours earlier). OUTCOME: Serum glucagon was measured every 30 minutes on each OGTT, enabling determination of the area under the glucagon curve (AUCglucagon). RESULTS: With the Mercodia assay, fasting glucagon was higher in the liraglutide arm than placebo at 12 weeks (P = 0.01), with no between-group differences at 24, 36, and 48 weeks. There was no difference in AUCglucagon between the groups at any visit. Mercodia and R&D Systems glucagon measurements correlated at postchallenge time points but not at fasting. CONCLUSION: The Mercodia assay did not replicate the R&D Systems glucagon findings. Although neither assay demonstrated lower postchallenge glucagonemia with chronic liraglutide last administered ∼24 hours earlier, the differential response reported by these assays precludes definitive conclusion and highlights the critical role of assay selection when measuring glucagon in clinical studies.
引用
- Kramer CK, Zinman B, Choi H, et al. Impact of the Glucagon Assay When Assessing the Effect of Chronic Liraglutide Therapy on Glucagon Secretion. J Clin Endocrinol Metab. 2017. PMID: 28472325. doi:10.1210/jc.2017-00928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。